Novo Nordisk Pharmatech A/S: Financial statements 2016
CVR: 13246149
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
Novo Nordisk Pharmatech A/S (CVR 13246149) has filed annual accounts for 2016. In 2016, the company reported revenue of DKK 669,077,000 and a net result of DKK 87,367,000 compared with DKK 92,104,000 the year before. That is an increase of 32.4% compared with the year before. The profit margin was 13.1%. Equity in the 2016 report amounted to DKK 468,288,000. The solvency ratio was 71.6%. The company had 158 employees in the financial year.
- Revenue
- DKK 669,077,000
- Gross Profit
- DKK 237,950,000
- Profit/Loss
- DKK 87,367,000
- Equity
- DKK 468,288,000
- Total Assets
- DKK 653,833,000
- Employees
- 158
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | 669.1M | 238M | 87.4M | 468.3M | 158 |
| 2015 | 505.2M | 228M | 92.1M | 400.9M | 150 |
| 2014 | 495.2M | 176.6M | 55.3M | 336.8M | 150 |
| 2013 | 498M | 170.7M | 46.7M | 304.5M | 141 |
Official annual report
Find more companies like Novo Nordisk Pharmatech A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2016
As of October 31, 2016, Peter Helt Jacobsen Haahr has left the board of directors of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2015. Revenue came to DKK 505,233,000, and the net result was DKK 92,104,000.
As of May 13, 2016, Joachim Juel Hagemeister has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 13, 2016, Vesna Maria Schneider has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 13, 2016, Lars Sørensen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 13, 2016, Erik Frederik Johannes Mortensen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 13, 2016, Camilla Mølbak Sønderris has left the board of directors of Novo Nordisk Pharmatech A/S.
About Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S is a Danish company of the type Aktieselskab based in Køge, founded in 1989. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named FEF CHEMICALS A/S and FERROSAN FINE CHEMICALS A/S. The management consists of Ulla Grove Krogsgaard Thomsen. The board consists of Mette Sofie Mørck Jarl (chair), Christian Brøgger Stolberg, Jacob Sten Petersen and Joachim Juel Hagemeister. The company is owned by NOVO NORDISK A/S. The company has 489 employees (2026). In 2025, the company reported revenue of DKK 1,041,584,000 and a net result of DKK 113,891,000 compared with DKK 60,619,000 the year before. Equity in the 2025 report amounted to DKK 2,441,318,000.
